Ligand Pharmaceuticals (LGND) Proxy filing summary

Executive summary

• Annual meeting scheduled for June 5, 2026, to be held virtually, with voting on key proposals including director elections, auditor ratification, executive compensation, and an amendment to the 2002 Stock Incentive Plan.

• The company reported strong financial performance in 2025, with royalty revenue up 48% and adjusted EPS up 42% over the prior year.

• Strategic investments and transactions, such as the Pelthos merger and new royalty agreements, contributed to portfolio growth and value creation.

• The company emphasizes a lean operating structure, disciplined capital deployment, and a diversified royalty portfolio.

Voting matters and shareholder proposals

• Election of eight directors for one-year terms.

• Ratification of Ernst & Young LLP as independent auditor for fiscal year ending December 31, 2026.

• Advisory vote on executive compensation (say-on-pay).

• Approval of amendment and restatement of the 2002 Stock Incentive Plan, including an increase in share reserve and changes to award mechanics.

Board of directors and corporate governance

• Board consists of eight nominees with diverse backgrounds in life sciences, finance, and regulatory affairs.

• Seven of eight directors are independent; CEO is the only non-independent member.

• Board committees include Audit, Nominating and Corporate Governance, and Human Capital Management and Compensation, plus two specialized committees for strategic transactions and science/technology.

• Directors receive a mix of cash and equity compensation, with updated retainer and award values effective April 2026.

• Stock ownership guidelines require directors to own shares equal to five times their annual retainer.